Marques CDL. Covid-19 and rheumatic diseases: it is time to better understand this association. J Rheumatol. 2021;48:318–20.

Article  CAS  PubMed  Google Scholar 

Mehta B, Pedro S, Ozen G, Kalil A, Wolfe F, Mikuls T, et al. Serious infection risk in rheumatoid arthritis compared with non-inflammatory rheumatic and musculoskeletal diseases: a US national cohort study. RMD Open. 2019;5:e000935.

Article  PubMed  PubMed Central  Google Scholar 

Au K, Reed G, Curtis JR, Kremer JM, Greenberg JD, Strand V, et al. High disease activity is associated with an increased risk of infection in patients with rheumatoid arthritis. Ann Rheum Dis. 2011;70:785–91.

Article  PubMed  Google Scholar 

Martinez A, Pacheco-Tena C, Vazquez-Mellado J, Burgos-Vargas R. Relationship between disease activity and infection in patients with spondyloarthropathies. Ann Rheum Dis. 2004;63:1338–40.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Bezzio C, Saibeni S, Variola A, Allocca M, Massari A, Gerardi V, et al. Outcomes of covid-19 in 79 patients with ibd in Italy: an ig-ibd study. Gut. 2020;69:1213–7.

Article  CAS  PubMed  Google Scholar 

Gianfrancesco M, Hyrich KL, Al-Adely S, Carmona L, Danila MI, Gossec L, et al. Characteristics associated with hospitalisation for covid-19 in people with rheumatic disease: data from the covid-19 global rheumatology alliance physician-reported registry. Ann Rheum Dis. 2020;79:859–66.

Article  CAS  PubMed  Google Scholar 

Ciurea A, Papagiannoulis E, Burki K, von Loga I, Micheroli R, Moller B, et al. Impact of the covid-19 pandemic on the disease course of patients with inflammatory rheumatic diseases: results from the Swiss clinical quality management cohort. Ann Rheum Dis. 2021;80:238–41.

Article  CAS  PubMed  Google Scholar 

Germano V, Cattaruzza MS, Osborn J, Tarantino A, Di Rosa R, Salemi S, et al. Infection risk in rheumatoid arthritis and spondyloarthropathy patients under treatment with dmards, corticosteroids and tnf-alpha antagonists. J Transl Med. 2014;12:77.

Article  PubMed  PubMed Central  Google Scholar 

Singh JA, Hossain A, Kotb A, Wells G. Risk of serious infections with immunosuppressive drugs and glucocorticoids for lupus nephritis: a systematic review and network meta-analysis. BMC Med. 2016;14:137.

Article  PubMed  PubMed Central  Google Scholar 

Fouque-Aubert A, Jette-Paulin L, Combescure C, Basch A, Tebib J, Gossec L. Serious infections in patients with ankylosing spondylitis with and without tnf blockers: a systematic review and meta-analysis of randomised placebo-controlled trials. Ann Rheum Dis. 2010;69:1756–61.

Article  CAS  PubMed  Google Scholar 

Voruganti A, Bowness P. New developments in our understanding of ankylosing spondylitis pathogenesis. Immunology. 2020;161:94–102.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Brewerton DA, Hart FD, Nicholls A, Caffrey M, James DC, Sturrock RD. Ankylosing spondylitis and hl-a 27. Lancet. 1973;1:904–7.

Article  CAS  PubMed  Google Scholar 

Schlosstein L, Terasaki PI, Bluestone R, Pearson CM. High association of an hl-a antigen, w27, with ankylosing spondylitis. N Engl J Med. 1973;288:704–6.

Article  CAS  PubMed  Google Scholar 

Mathieu A, Cauli A, Fiorillo MT, Sorrentino R. Hla-b27 and ankylosing spondylitis geographic distribution as the result of a genetic selection induced by malaria endemic? A review supporting the hypothesis. Autoimmun Rev. 2008;7:398–403.

Article  PubMed  Google Scholar 

Mathieu A, Paladini F, Vacca A, Cauli A, Fiorillo MT, Sorrentino R. The interplay between the geographic distribution of hla-b27 alleles and their role in infectious and autoimmune diseases: a unifying hypothesis. Autoimmun Rev. 2009;8:420–5.

Article  CAS  PubMed  Google Scholar 

Rodrigues KF, Fariaearantes TE, Muccioli C, Neto JL, Pinheiro MM. Incidence of toxoplasma retinochoroiditis in patients with ankylosing spondylitis after using tnf-α blockers. Parasitol Int. 2013;62:272–5.

Article  PubMed  Google Scholar 

den Uyl D, van der Horst-Bruinsma IE, van Agtmael M. Progression of HIV to AIDS: a protective role for hla-b27? AIDS Rev. 2004;6:89–96.

Google Scholar 

Haberman R, Axelrad J, Chen A, Castillo R, Yan D, Izmirly P, et al. Covid-19 in immune-mediated inflammatory diseases - case series from New York. N Engl J Med. 2020;383:85–8.

Article  PubMed  Google Scholar 

Sanchez-Piedra C, Diaz-Torne C, Manero J, Pego-Reigosa JM, Rua-Figueroa I, Gonzalez-Gay MA, et al. Clinical features and outcomes of covid-19 in patients with rheumatic diseases treated with biological and synthetic targeted therapies. Ann Rheum Dis. 2020;79:988–90.

Article  CAS  PubMed  Google Scholar 

Monti S, Balduzzi S, Delvino P, Bellis E, Quadrelli VS, Montecucco C. Clinical course of covid-19 in a series of patients with chronic arthritis treated with immunosuppressive targeted therapies. Ann Rheum Dis. 2020;79:667–8.

Article  CAS  PubMed  Google Scholar 

Marques C, Kakehasi AM, Gomides APM, Paiva EDS, Dos Reis Neto ET, Pileggi GCS, et al. Reumacov Brasil Registry: a Brazilian cohort of patients with immuno-mediated chronic inflammatory diseases infected by sars-cov-2. JMIR Res Protoc. 2020;9:e24357.

Article  PubMed  PubMed Central  Google Scholar 

Marques CDL, Kakehasi AM, Pinheiro MM, Mota LMH, Albuquerque CP, Silva CR, et al. High levels of immunosuppression are related to unfavourable outcomes in hospitalised patients with rheumatic diseases and covid-19: first results of Reumacov Brasil Registry. RMD Open. 2021;7:e001461.

Article  PubMed  Google Scholar 

Brasil. Boletim epidemiológico - doença pelo coronavírus 2019 - ampliação da vigilância, medidas não farmacológicas e descentralização do diagnóstico laboratorial. In: Saúde Md, editor. Brasil; 2020.

Rudwaleit M, van der Heijde D, Landewe R, Listing J, Akkoc N, Brandt J, et al. The development of assessment of spondyloarthritis international society classification criteria for axial spondyloarthritis (part II): validation and final selection. Ann Rheum Dis. 2009;68:777–83.

Article  CAS  PubMed  Google Scholar 

Taylor W, Gladman D, Helliwell P, Marchesoni A, Mease P, Mielants H, et al. Classification criteria for psoriatic arthritis: development of new criteria from a large international study. Arthritis Rheum. 2006;54:2665–73.

Article  PubMed  Google Scholar 

Garrett S, Jenkinson T, Kennedy LG, Whitelock H, Gaisford P, Calin A. A new approach to defining disease status in ankylosing spondylitis: the bath ankylosing spondylitis disease activity index. J Rheumatol. 1994;21:2286–91.

CAS  PubMed  Google Scholar 

Machado PM, Landewe R, Heijde DV. Assessment of SpondyloArthritis international S. Ankylosing spondylitis disease activity score (asdas): 2018 update of the nomenclature for disease activity states. Ann Rheum Dis. 2018;77:1539–40.

Article  PubMed  Google Scholar 

Coates LC, Fransen J, Helliwell PS. Defining minimal disease activity in psoriatic arthritis: a proposed objective target for treatment. Ann Rheum Dis. 2010;69:48–53.

Article  CAS  PubMed  Google Scholar 

Hasseli R, Mueller-Ladner U, Hoyer BF, Krause A, Lorenz HM, Pfeil A, et al. Older age, comorbidity, glucocorticoid use and disease activity are risk factors for covid-19 hospitalisation in patients with inflammatory rheumatic and musculoskeletal diseases. RMD Open. 2021;7:e001464.

Article  PubMed  Google Scholar 

Salvarani C, Bajocchi G, Mancuso P, Galli E, Muratore F, Boiardi L, et al. Susceptibility and severity of covid-19 in patients treated with bdmards and tsdmards: a population-based study. Ann Rheum Dis. 2020;79:986–8.

Article  PubMed  Google Scholar 

Cordtz R, Lindhardsen J, Soussi BG, Vela J, Uhrenholt L, Westermann R, et al. Incidence and severeness of covid-19 hospitalisation in patients with inflammatory rheumatic disease: a nationwide cohort study from Denmark. Rheumatology (Oxford). 2020;60:159–67.

Google Scholar 

Wolfe F, Caplan L, Michaud K. Treatment for rheumatoid arthritis and the risk of hospitalization for pneumonia: associations with prednisone, disease-modifying antirheumatic drugs, and anti-tumor necrosis factor therapy. Arthritis Rheum. 2006;54:628–34.

Article  CAS  PubMed  Google Scholar 

Boschi D, Pippione AC, Sainas S, Lolli ML. Dihydroorotate dehydrogenase inhibitors in anti-infective drug research. Eur J Med Chem. 2019;183:111681.

Article  CAS  PubMed  Google Scholar 

Gokarn A, Toshniwal A, Pathak A, Arora S, Bonda A, Punatar S, et al. Use of leflunomide for treatment of cytomegalovirus infection in recipients of allogeneic stem cell transplant. Biol Blood Marrow Transplant. 2019;25:1832–6.

Article  CAS  PubMed  Google Scholar 

Levi ME, Mandava N, Chan LK, Weinberg A, Olson JL. Treatment of multidrug-resistant cytomegalovirus retinitis with systemically administered leflunomide. Transpl Infect Dis. 2006;8:38–43.

Article  CAS  PubMed  Google Scholar 

Teschner S, Burst V. Leflunomide: a drug with a potential beyond rheumatology. Immunotherapy. 2010;2:637–50.

Article  CAS  PubMed  Google Scholar 

Josephson MA, Javaid B, Kadambi PV, Meehan SM, Williams JW. Leflunomide in solid organ transplantation and polyoma virus infection. Adv Exp Med Biol. 2006;577:255–65.

Article  CAS  PubMed  Google Scholar